Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Opus Genetics ( (IRD) ) has shared an update.
Opus Genetics announced the appointment of Rob Gagnon as Chief Financial Officer on September 2, 2025. Gagnon, an experienced biotech executive, brings over two decades of financial leadership, having raised significant capital and guided companies through IPOs and strategic transactions. His expertise is expected to support Opus in advancing its clinical pipeline and achieving regulatory milestones, thereby enhancing its position in the gene therapy market for inherited retinal diseases.
The most recent analyst rating on (IRD) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The company’s pipeline includes AAV-based gene therapies targeting conditions such as Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa, with lead candidates like OPGx-LCA5 and OPGx-BEST1. Opus is also advancing Phentolamine Ophthalmic Solution 0.75% for presbyopia and other visual disturbances.
Average Trading Volume: 434,246
Technical Sentiment Signal: Sell
Current Market Cap: $73.09M
See more insights into IRD stock on TipRanks’ Stock Analysis page.